Di Molfetta Sergio, Daniele Antonella, Gerardi Chiara, Allocati Eleonora, Minoia Carla, Loseto Giacomo, Giorgino Francesco, Guarini Attilio, De Sanctis Vitaliana
Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, 70124 Bari, Italy.
Experimental Oncology and Biobank Management Unit, RCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
Cancers (Basel). 2022 Mar 10;14(6):1439. doi: 10.3390/cancers14061439.
Overall survival after lymphoma has improved in recent years, but the high prevalence of late treatment-related sequelae has been observed as a counterpart.
In this systematic review, FIL researchers aimed to: (i) estimate the incidence or prevalence of late endocrine-metabolic sequelae, (ii) evaluate the effects of modern therapeutic approaches on incidence or prevalence of late endocrine-metabolic sequelae, and (iii) determine whether there is evidence of follow-up schemes for their screening/early diagnosis in the subset of long-term classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) survivors treated at adult age. The MEDLINE, Embase and the Cochrane Library databases were searched for relevant articles published up to October, 2020. The study selection process was conducted by three independent reviewers and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A risk of bias assessment was performed using the Cochrane tool for randomized trials and the Newcastle-Ottawa Scale for observational studies.
In the final analysis, eight studies were included, four of which focused on thyroid disease, two on gonadal dysfunction, one on bone disease and one on metabolic syndrome. Hypothyroidism was reported in up to 60% of adult cHL survivors and was frequently recorded even with modern radiotherapy approaches. Menopause occurred in 52-72% of women after chemotherapy. An 86% reduction in vertebral density was reported following R-CHOP-like chemotherapy. Sarcopenia and metabolic syndrome were reported in 37.9% and 60% of patients, respectively. No validated screening protocols were found for the early diagnosis of long-term treatment-related endocrine and metabolic sequelae, thus the authors finally suggest the execution of screening exams according to the risk category which were identified in the epidemiologic studies.
近年来淋巴瘤患者的总生存率有所提高,但与之相对的是,治疗相关晚期后遗症的高发生率也已被观察到。
在这项系统评价中,FIL研究人员旨在:(i)估计晚期内分泌代谢后遗症的发生率或患病率;(ii)评估现代治疗方法对晚期内分泌代谢后遗症发生率或患病率的影响;(iii)确定在成年期接受治疗的长期经典型霍奇金淋巴瘤(cHL)和弥漫性大B细胞淋巴瘤(DLBCL)幸存者亚组中,是否有证据表明存在针对其筛查/早期诊断的随访方案。检索了MEDLINE、Embase和Cochrane图书馆数据库中截至2020年10月发表的相关文章。研究选择过程由三名独立评审员进行,并根据系统评价和Meta分析的首选报告项目(PRISMA)指南进行报告。使用Cochrane随机试验工具和纽卡斯尔-渥太华量表对观察性研究进行偏倚风险评估。
在最终分析中,纳入了八项研究,其中四项聚焦于甲状腺疾病,两项聚焦于性腺功能障碍,一项聚焦于骨骼疾病,一项聚焦于代谢综合征。据报道,高达60%的成年cHL幸存者患有甲状腺功能减退症,即使采用现代放疗方法,该疾病也经常被记录到。化疗后,52%-72%的女性出现绝经。据报道,接受类似R-CHOP方案化疗后,椎体密度降低了86%。分别有37.9%和60%的患者报告出现肌肉减少症和代谢综合征。未发现用于长期治疗相关内分泌和代谢后遗症早期诊断的有效筛查方案,因此作者最终建议根据流行病学研究中确定的风险类别进行筛查检查。